Glenmark Pays USD 25 Million to Settle US Pricing Case
By Rediff Money Desk, New Delhi Sep 05, 2024 10:57
Glenmark Pharmaceuticals has agreed to pay USD 25 million to settle a US Department of Justice investigation into pricing practices related to a generic drug. The settlement includes restitution and does not admit liability.
![Glenmark Pays USD 25 Million to Settle US Pricing Case](https://im.rediff.com/money/2023/may/24glenmark.jpg)
Photograph: PTI Photo
New Delhi, Sep 5 (PTI) Glenmark Pharmaceuticals has agreed to pay USD 25 million as part of a settlement with the US Department of Justice regarding a case related to the pricing of a generic drug.
Glenmark Pharmaceuticals Inc, USA, a wholly-owned subsidiary of the Mumbai-based drug maker, has agreed to pay the amount in six installments over five years, with interest on the settlement amount at a rate of 4.25 per cent per annum from May 28, 2024, the company said in a late night regulatory filing on Wednesday.
The Civil Division of the US Department of Justice has concluded its False Claims Act and Anti-Kickback Statute investigation in a settlement with Glenmark Pharmaceuticals Inc, USA, it said.
"The settlement amount and interest on the settlement amount constitute restitution," the drug maker said.
As noted, the settlement does not contain any admission of liability by the company, except to the extent already admitted by Glenmark in the August 2023 Deferred Prosecution Agreement, it added.
Last year, Glenmark had stated that it has entered into a three-year deferred prosecution agreement with the US Department of Justice involving pricing practices by former employees relating to the generic drug pravastatin between 2013 and 2015.
Shares of Glenmark were trading 1.22 per cent up at Rs 1,708.25 apiece on the BSE.
Glenmark Pharmaceuticals Inc, USA, a wholly-owned subsidiary of the Mumbai-based drug maker, has agreed to pay the amount in six installments over five years, with interest on the settlement amount at a rate of 4.25 per cent per annum from May 28, 2024, the company said in a late night regulatory filing on Wednesday.
The Civil Division of the US Department of Justice has concluded its False Claims Act and Anti-Kickback Statute investigation in a settlement with Glenmark Pharmaceuticals Inc, USA, it said.
"The settlement amount and interest on the settlement amount constitute restitution," the drug maker said.
As noted, the settlement does not contain any admission of liability by the company, except to the extent already admitted by Glenmark in the August 2023 Deferred Prosecution Agreement, it added.
Last year, Glenmark had stated that it has entered into a three-year deferred prosecution agreement with the US Department of Justice involving pricing practices by former employees relating to the generic drug pravastatin between 2013 and 2015.
Shares of Glenmark were trading 1.22 per cent up at Rs 1,708.25 apiece on the BSE.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Rama Steel Tubes
- 13.90 (+ 19.93)
- 45705124
- GACM Technologies
- 1.65 ( -4.62)
- 27203996
- Sunshine Capital
- 2.55 (+ 4.94)
- 21813664
- Vodafone Idea L
- 15.09 (+ 1.75)
- 21038619
- GTL Infrastructure
- 2.56 ( -1.16)
- 15858604
MORE NEWS
![Ashok Leyland &...](https://im.rediff.com/80-80/money/2024/may/14commercial-vehicle-ashok-leyland.jpg)
Ashok Leyland & Bandhan Bank Partner for...
Ashok Leyland and Bandhan Bank have partnered to offer customized vehicle finance...
![INDIAsize...](https://im.rediff.com/80-80/money/2017/jun/02it.jpg)
INDIAsize Initiative: Standardized Measurements...
India's Textiles Minister Giriraj Singh announces the upcoming launch of the INDIAsize...
![Singapore, India...](https://im.rediff.com/80-80/money/2024/may/01semiconductor1.jpg)
Singapore, India Partner on Semiconductor...
Singapore and India have signed an MoU to collaborate on semiconductor development,...